Objectives: To observe the impact of rapamycin on peritoneal fibrosis and peritoneal transport function in a rat model of peritoneal fibrosis. Methods: A total of 40 male SD rats were randomly divided into five groups, with 8 rats in each group. Group N was the normal control. In group NS, the rats were injected daily with 20 ml of saline intraperitoneally. In groups GLU, L-RAPA and H-RAPA, rats were injected daily with 20 ml of 4.25% peritoneal dialysis solution intraperitoneally, together with 150 µg of lipopolysaccharide on days 1, 3, 5 and 7. Rapamycin was administered to groups L-RAPA (250 µg/day) and H-RAPA (500 µg/day) intragastrically. On days 21 and 35, 4 rats from each group were selected to evaluate their peritoneal transport function (ultrafiltration volume, D2/D₀ ratio). The parietal peritoneal membrane from the rats was used for pathological study. Light microscopy (HE staining and VG staining) was used to assess the morphological changes. The expression levels of Col I, α-SMA, TGF-β1, Reca and Ki67 in the parietal peritoneal membrane were observed by immunohistochemistry. Results: The ultrafiltration volume and D2/D₀ ratio decreased in group GLU compared with group N on day 21 (p < 0.05) and further decreased on day 35 (p < 0.01), whereas such a significant change was not observed in group L-RAPA or H-RAPA. Furthermore, severe loss of the peritoneal mesothelial cells, exposure of the collagen matrix under the mesothelial cells, and infiltration of fibroblasts and various inflammatory cells were detected in group GLU on days 21 and 35. The thickness of the submesothelial compact zone significantly increased in group GLU compared with group N (p < 0.01). However, in groups L-RAPA and H-RAPA, the morphological changes were clearly alleviated, and the submesothelial compact zone was thinner than in group GLU (p < 0.01). The expression levels of Col I, α-SMA, TGF-β1, Ki67 and Reca in the peritoneal membrane were significantly increased in group GLU compared with group N on days 21 and 35 (p < 0.01), whereas these changes were significantly attenuated in groups L-RAPA and H-RAPA compared with group GLU (p < 0.01). Conclusions: Rapamycin had an obvious effect in inhibiting peritoneal fibrosis and improving peritoneal membrane transport function.

Keywords:
Rapamycin, Peritoneal fibrosis, Peritoneal dialysis, Peritoneal membrane transport function
1.
Chung SH, Heimbürger O, Lindholm B: Poor outcomes for fast transporters on PD: the rise and fall of a clinical concern. Semin Dial 2008;21:7–10.
2.
Brimble KS, Walker M, Margetts PJ, et al: Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006;17:2591–2598.
3.
Mehrad B, Burdick MD, Strieter RM: Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol 2009;41:1708–1718.
4.
Patsenker E, Schneider V, Ledermann M, et al: Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 2011;55:388–398.
5.
Yoshizaki A, Yanaba K, Yoshizaki A, et al: Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 2010;62:2476–2487.
6.
Wu MJ, Wen MC, Chiu YT, et al: Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 2006;69:2029–2036.
7.
Li PK, Szeto CC, Piraino B, et al: Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010;30:393–423.
8.
Oshiro N, Yoshino K, Hidayat S, et al: Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. J Genes Cell 2004;9:359–366.
9.
Tao Y, Kim J, Schrier RW, et al: Rapamycin markedly slows disease progression in a rat model of polycystic disease. J Am Soc Nephrol 2005;16:46–51.
10.
Wahl PR, Serra AL, Le Hir M, et al: Inhibition of mTOR with sirolimus slows disease progression in Han: SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006;21:598–604.
11.
Sakaguchi M, Isono M, Isshiki K, et al: Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun 2006;340:296–301.
12.
Yang Y, Wang J, Qin L, et al: Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 2007;27:495–502.
13.
Lloberas N, Cruzado JM, Franquesa M, et al: Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006;17:1395–1404.
14.
Stylianou K, Petrakis I, Mavroeidi V, et al: The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and down-regulated by rapamycin. Nephrol Dial Transplant 2011;26:498–508.
15.
Lieberthal W, Fuhro R, Andry CC, et al: Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001;281:F693–F706.
16.
Lieberthal W, Fuhro R, Andry C, et al: Rapamycin delays but does not prevent recovery from acute renal failure: role of acquired tubular resistance. Transplantation 2006;82:17–22.
17.
Schilte MN, Celie JW, Wee PM, et al: Factors contributing to peritoneal tissue remodeling in peritoneal dialysis. Perit Dial Int 2009;29:605–617.
18.
Shunsuke T, Yoshihiko T, Ayumu N, et al: Mizoribine suppresses the progression of experimental peritoneal fibrosis in a rat model. Nephron Exp Nephrol 2009;112:e59–e69.
19.
Margetts PJ, Kolb M, Gait T, et al: Gene transfer of transforming growth factor-β1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001;12:2029–2039.
20.
Gunal AI, Duman S, Sen S, et al: By reducing TGF-β1, octreotide lessens the peritoneal derangements induced by a high glucose solution. J Nephrol 2001;14:184–189.
21.
Margetts PJ, Gyorffy S, Kolb M, et al: Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002;13:721–728.
22.
Margetts PJ, Kolb M, Yu L, et al: Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol 2002;160:2285–2294.
23.
Ogata S, Naito T, Yorioka N, et al: Effect of lactate and bicarbonate on human peritoneal mesothelial cells, fibroblasts and vascular endothelial cells, and the role of basic fibroblast growth factor. Nephrol Dial Transplant 2004;19:2831–2837.
24.
Zweers MM, de Waart DR, Smit W, et al: Growth factors VEGF and TGF-β1 in peritoneal dialysis. J Lab Clin Med 1999;134:124–132.
25.
Gerdes J, Schwab U, Lemke H, et al: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13–20.
26.
Lopez F, Belloc F, Lacombe F, et al: Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry 1991;12:42–49.
27.
Patel P, Sekiguchi Y, Oh KH, et al: Smad3-dependent and -independent pathways are involved in peritoneal membrane injury. Kidney Int 2010;77:319–328.
28.
Duman S, Bozkurt D, Sipahi S, et al: Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model. Adv Perit Dial 2008;24:104–110.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.